GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Outperform
BIIB
up 549.78 %

Biogen Idec Inc (BIIB) rated Outperform by Leerink Swann

Posted on: Monday,  Jul 23, 2012  8:29 AM ET by Leerink Swann

Leerink Swann rated Outperform Biogen Idec Inc (NASDAQ: BIIB) on 07/23/2012. Previously Leerink Swann rated Outperform Biogen Idec Inc (NASDAQ: BIIB)
on 07/14/2009., when the stock price was $46.86. Since then, Biogen Idec Inc has gained 549.79% as of 01/07/2016's recent price of $304.49.
If you would have followed the previous Leerink Swann 's recommendation on BIIB, you would have gained 549.78% of your investment in 2368 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/23/2012 8:29 AM Buy
None
138.84
as of 12/31/2012
1 Week down  -1.81 %
1 Month down  -1.82 %
3 Months down  -1.90 %
1 YTD up  33.00 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/14/2009 8:25 AM Buy
None
46.86 55.00
10/22/2008 8:25 AM Hold
None
42.06

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy